Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma

Trial Profile

Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs Itraconazole (Primary) ; Itraconazole
  • Indications Allergic bronchopulmonary aspergillosis
  • Focus Adverse reactions; First in man
  • Sponsors Pulmatrix
  • Most Recent Events

    • 21 Nov 2018 According to a Pulmatrix media release, results of this trial were presented as poster at the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.
    • 21 Nov 2018 Results presented in a Pulmatrix media release.
    • 15 Nov 2018 According to a Pulmatrix media release, data from this trial will be presented at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top